VolitionRx Limited is a clinical-stage life sciences company. The company has a market cap of $74.39 million. The Firm is focused on developing blood diagnostic tests for detecting and diagnosing cancer and other diseases. It currently has negative earnings. The Firm has developed approximately 30 blood assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease.
The post Anticipated Eps Rise for VolitionRX Ltd (VNRX) appeared first on Octafinance.